The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of treatment for initial type 1 diabetes is safe and effective.
Type 1 diabetes mellitus (T1DM)is characterized by the autoimmune destruction of the pancreatic β cells.Patients require multiple daily insulin injections throughout their lives as well as close monitoring of their diet and blood sugar levels to prevent complications. The investigators hope umbilical cord Mesenchymal Stem Cells could not only address the need for β-cell replacement but also control of the autoimmune response to β cells.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
Stem Cell Research Center of Medical School Hospital of Qingdao University
Qingdao, Shandong, China
C peptide release test
Time frame: 3 months
Exogenous insulin dose
Time frame: 3 months
blood glucose
Time frame: 3 months
glycosylated Hemoglobin A1c
Time frame: 3 months
Number of severe and documented hypoglycemic events
Time frame: 3 months
Immunologic reconstitution parameters
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.